Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Change At GSK's Top, With Vaccines Chief Luc Debruyne Set To Say 'Adieu'

Executive Summary

The head of GSK's vaccines division, Luc Debruyne, is leaving the company at the end of the year.

You may also be interested in...



Shingrix Seen Replacing Zostavax In EU & US as Shingles Standard Of Care

Shingrix is likely to replace Merck & Co's Zostavax as the preferred shingles vaccine in the EU and US, following the GSK product’s approval in the US and recent positive opinion in the EU. Sales in major markets could approach $700m by 2025.

GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In

"Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company," stated GSK's out-going CEO Andrew Witty, as Abbas Hussain decides to leave the company having lost out on the top job, which went to Emma Walmsley. His successor will be AstraZeneca's Luke Miels.

GSK's Vaccines Chief Slaoui To Follow Witty Out The Door

One person definitely not lining up to take over from Sir Andrew Witty when he retires from GlaxoSmithKline PLC in March 2017 is its vaccines chief and former head of R&D Dr. Moncef Slaoui. He is to retire from the company in June 2017.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC123249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel